Publix Alerts Consumers to Potential Hazard in Ground Beef
Food safety and consumer confidence in the food system are vital. Companies must provide allergen labels and ensure that products are free of potential foreign materials. When an issue impacting the packaged food arises, a company releases a recall of these food products.Recently, Publix voluntarily recalled Market Ground Beef Products, which had been sold in a single Gainesville, Georgia store. Other stores were not affected. The potentially hazardous products were sold on June 26, 2025. Ground beef sold after this date was not impacted.
Maria Brous, Publix director of communications, said in a company statement, 'As part of our commitment to food safety, potentially impacted product has been removed from the store shelves.' The products were removed from store shelves.
Although the Publix alert did not clarify the potential foreign material contamination, shoppers were urged to throw away the beef or return it to the store for a full refund. Consumers concerned about their purchase can contact Publix Customer Care.
Related:
In recent months, Publix has been plagued with several food recalls. Earlier this year, pork and beef products were recalled. Both issues stemmed from the potential presence of foreign material.
Those recalls were made voluntarily by the company. A voluntary recall helps to swiftly remove the product from store shelves and alerts consumers quickly to the potential hazard.
Foreign material contamination is considered a severe issue. Companies are required to alert the FDA within 24 hours of confirmation. Examples of this type of recall include plastic in acai bowls, metal in an artichoke dip or rocks in canned vegetables.
Maintaining consumer confidence in the food system is vital. While food recalls can be unnerving, they are important.Publix Alerts Consumers to Potential Hazard in Ground Beef first appeared on Men's Journal on Jul 8, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio
Business Upturn
2 hours ago
- Business Upturn
SuperYou launches protein powder with Indian Masala Chai flavour, alongside chocolate and cold coffee variants
Actor Ranveer Singh's health brand SuperYou, co-founded with Nikunj Biyani, has entered the protein supplements market with the launch of SuperYou Pro, a clean, gut-friendly protein powder powered by bio-fermented yeast protein technology. While the range includes classic Chocolate, bold Cold Coffee, and neutral Unflavoured options, the highlight is the uniquely Indian Masala Chai flavour, designed to bring familiar taste to fitness-focused consumers. The launch blends taste innovation with performance nutrition, catering to gym-goers, athletes, and active lifestyle users. A flavour-packed protein revolution SuperYou Pro delivers 24–27g of clean, complete protein per serving, all nine essential amino acids, zero allergens, and a PDCAAS score of 1.0—on par with whey. The bio-fermentation process ensures smoother absorption and better digestibility, making it suitable for vegans and those avoiding dairy, soy, and gluten. Nikunj Biyani, Co-founder of SuperYou, said, 'We wanted to create a protein powder that's as enjoyable as it is effective. The Masala Chai flavour is a nod to India's cultural roots while keeping health at the forefront.' Market-ready and certified The protein is NABL verified, quality backed by SGS China and SciEp Australia, and made in a US FDA and GMP-certified facility. Priced at ₹3,000/kg, it is available online at Amazon, Flipkart, Blinkit, Zepto, Instamart, and in stores like Wellness Forever, Noble Chemist, Ratnadeep, and 7-Eleven. With its distinctive flavours and science-backed formulation, SuperYou Pro aims to make protein consumption in India more exciting, accessible, and culturally connected. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Insider
9 hours ago
- Business Insider
Travere Therapeutics price target raised to $34 from $32 at Citi
Citi raised the firm's price target on Travere Therapeutics (TVTX) to $34 from $32 and keeps a Buy rating on the shares. The firm sees meaningful potential upside for the shares with two near-term FDA action dates for Travere. Citi upped the company's estimates to reflect continued demand growth for Filspari in immunoglobulin A nephropathy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
